Please login to the form below

Not currently logged in
Email:
Password:

Biktarvy

This page shows the latest Biktarvy news and features for those working in and with pharma, biotech and healthcare.

Janssen’s single tablet Symtuza gains NHS England funding 

Janssen’s single tablet Symtuza gains NHS England funding 

Gilead gained European approval for its own new single table regimen, Biktarvy in June, hot on the heels of ViiV’s rival Juluca. ... Biktarvy is a combination of integrase inhibitor bictegravir with Gilead’s already blockbuster Descovy, a combination

Latest news

More from news
Approximately 4 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics